$LTBR
LIGHTBRIDGE Corp

2023 Q1 Form 10-K Financial Statement

#000147793223001946 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.866M $2.113M $7.490M
YoY Change -2.49% 1.98% 5.0%
% of Gross Profit
Research & Development $448.0K $68.65K $669.8K
YoY Change 70.47% -75.84% -50.98%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.314M $2.087M $8.160M
YoY Change 6.32% -8.78% -4.28%
Operating Profit -$2.283M -$7.787M
YoY Change 11.2% -1.14%
Interest Expense $256.4K $179.0K $289.4K
YoY Change 7203.99% 1445.51% 79.26%
% of Operating Profit
Other Income/Expense, Net $289.4K
YoY Change 592.08%
Pretax Income -$2.027M -$1.908M -$7.498M
YoY Change -1.12% -17.08% -4.31%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$2.027M -$1.908M -$7.498M
YoY Change -1.12% -17.08% -4.31%
Net Earnings / Revenue
Basic Earnings Per Share -$0.17 -$0.69
Diluted Earnings Per Share -$0.17 -$0.17 -$0.69
COMMON SHARES
Basic Shares Outstanding 12.13M shares 11.58M shares 10.83M shares
Diluted Shares Outstanding 11.67M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.05M $28.90M $28.90M
YoY Change -0.62% 16.78% 16.78%
Cash & Equivalents $28.05M $28.90M $28.90M
Short-Term Investments
Other Short-Term Assets $393.4K $115.3K $115.3K
YoY Change -29.59% 1.6% 1.6%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $28.44M $29.02M $29.02M
YoY Change -1.18% 16.71% 16.71%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $100.0K
YoY Change 0.0%
Long-Term Investments
YoY Change
Other Assets $345.0K $345.0K $345.0K
YoY Change
Total Long-Term Assets $453.2K $453.2K $453.2K
YoY Change 346.18% 346.16% 346.18%
TOTAL ASSETS
Total Short-Term Assets $28.44M $29.02M $29.02M
Total Long-Term Assets $453.2K $453.2K $453.2K
Total Assets $28.90M $29.47M $29.47M
YoY Change 0.04% 18.05% 18.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $176.0K $150.3K $150.3K
YoY Change 75.98% 50.33% 50.33%
Accrued Expenses $400.0K $200.0K $200.0K
YoY Change 300.0% 100.0% 100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $576.0K $350.3K $350.3K
YoY Change 27.2% 104.25% 104.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $576.0K $350.3K $350.3K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $576.0K $350.3K $350.3K
YoY Change 27.2% 104.25% 104.25%
SHAREHOLDERS EQUITY
Retained Earnings -$146.5M -$144.5M
YoY Change 5.47%
Common Stock $12.13K $11.90K
YoY Change 21.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.32M $29.12M $29.12M
YoY Change
Total Liabilities & Shareholders Equity $28.90M $29.47M $29.47M
YoY Change 0.04% 18.05% 18.05%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$2.027M -$1.908M -$7.498M
YoY Change -1.12% -17.08% -4.31%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.580M -$2.659M -$6.763M
YoY Change -18.3% 18.56% -38.72%
INVESTING ACTIVITIES
Capital Expenditures $470.00 $6.640K
YoY Change -141.45%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$470.00 -$6.642K
YoY Change -58.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $11.03M
YoY Change -25.6%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $731.1K 275.2K $10.92M
YoY Change -86.49% -97.47% -23.45%
NET CHANGE
Cash From Operating Activities -$1.580M -2.659M -$6.763M
Cash From Investing Activities $0.00 -470.0 -$6.642K
Cash From Financing Activities $731.1K 275.2K $10.92M
Net Change In Cash -$848.7K -2.385M $4.152M
YoY Change -124.39% -127.68% 29.12%
FREE CASH FLOW
Cash From Operating Activities -$1.580M -$2.659M -$6.763M
Capital Expenditures $470.00 $6.640K
Free Cash Flow -$2.660M -$6.770M
YoY Change 18.58% -38.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Operating Expenses
OperatingExpenses
8525054 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
289435 usd
CY2022 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1812 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7158558 usd
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001084554
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9759223 shares
CY2022 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
0 shares
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 usd
CY2022 ltbr Income Tax Expense Benefits
IncomeTaxExpenseBenefits
0 usd
CY2021 ltbr Income Tax Expense Benefits
IncomeTaxExpenseBenefits
0 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation Disposition Of Assets
EffectiveIncomeTaxRateReconciliationDispositionOfAssets
0.25 pure
CY2021Q4 ltbr Net Operating Loss Carry Forward
NetOperatingLossCarryForward
54000000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
188588 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
45577 shares
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-34487
CY2022 dei Entity Registrant Name
EntityRegistrantName
LIGHTBRIDGE CORPORATION
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1975651
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
11710 Plaza America Drive,
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2000
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Reston
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
VA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20190
CY2022 dei City Area Code
CityAreaCode
571
CY2022 dei Local Phone Number
LocalPhoneNumber
730-1200
CY2022 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2022 dei Trading Symbol
TradingSymbol
LTBR
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
49899793 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12126030 shares
CY2022 dei Auditor Name
AuditorName
BDO USA, LLP
CY2022 dei Auditor Location
AuditorLocation
Philadelphia, PA
CY2022 dei Auditor Firm
AuditorFirmId
243
CY2022Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
345000 usd
CY2021Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
0 usd
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9759223 shares
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1366496 usd
CY2022 us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
0 usd
CY2021 us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
119641 usd
CY2022 ltbr Contributed Services Research And Development
ContributedServicesResearchAndDevelopment
372612 usd
CY2021 ltbr Contributed Services Research And Development
ContributedServicesResearchAndDevelopment
527927 usd
CY2022 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
372612 usd
CY2021 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
647568 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-7787292 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-7877486 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
289435 usd
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
8127 usd
CY2022 us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
0 usd
CY2021 us-gaap Foreign Currency Transaction Gain Before Tax
ForeignCurrencyTransactionGainBeforeTax
33694 usd
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
41821 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7497857 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7835665 usd
CY2022 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 usd
CY2021 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
477991 usd
CY2022 ltbr Debt Conversion Original Debt Amount
DebtConversionOriginalDebtAmount
0 usd
CY2021 ltbr Debt Conversion Original Debt Amount
DebtConversionOriginalDebtAmount
-213720 usd
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-3509328 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7497857 usd
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12036704 usd
CY2022 ltbr Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-0.69
CY2021 ltbr Earnings Per Share Basic And Diluted1
EarningsPerShareBasicAndDiluted1
-1.71
CY2022 ltbr Weighted Average Number Of Diluted Shares Outstanding1
WeightedAverageNumberOfDilutedSharesOutstanding1
10834574 shares
CY2021 ltbr Weighted Average Number Of Diluted Shares Outstanding1
WeightedAverageNumberOfDilutedSharesOutstanding1
7035510 shares
CY2022 us-gaap Profit Loss
ProfitLoss
7497857 usd
CY2021 us-gaap Profit Loss
ProfitLoss
7835665 usd
CY2022 ltbr Common Stock Issued For Services
CommonStockIssuedForServices
45000 usd
CY2021 ltbr Common Stock Issued For Services
CommonStockIssuedForServices
254994 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
842704 usd
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
826493 usd
CY2021 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-59008 usd
CY2022 ltbr Increase Decrease In Prepaid Project Costs
IncreaseDecreaseInPrepaidProjectCosts
345000 usd
CY2021 ltbr Increase Decrease In Prepaid Project Costs
IncreaseDecreaseInPrepaidProjectCosts
0 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
193810 usd
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-140919 usd
CY2022 ltbr Increase Decrease In Accrued Legal Settlements Costs
IncreaseDecreaseInAccruedLegalSettlementsCosts
0 usd
CY2021 ltbr Increase Decrease In Accrued Legal Settlements Costs
IncreaseDecreaseInAccruedLegalSettlementsCosts
-4200000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6763155 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11036089 usd
CY2022 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
6642 usd
CY2021 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
16021 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6642 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16021 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11026785 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14821354 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 usd
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
270857 usd
CY2022 ltbr Payments For Taxes Related To Net Share Settlement Of Equity Awards
PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
104604 usd
CY2021 ltbr Payments For Taxes Related To Net Share Settlement Of Equity Awards
PaymentsForTaxesRelatedToNetShareSettlementOfEquityAwards
824153 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10922181 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14268058 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4152384 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3215948 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24747613 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21531665 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28899997 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
24747613 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022 ltbr Accumulated Preferred Stock Dividend
AccumulatedPreferredStockDividend
0 usd
CY2021 ltbr Accumulated Preferred Stock Dividend
AccumulatedPreferredStockDividend
691711 usd
CY2022 ltbr Exchanges Of Preferred Stock Series A And B To Common Stock
ExchangesOfPreferredStockSeriesAAndBToCommonStock
0 usd
CY2021 ltbr Exchanges Of Preferred Stock Series A And B To Common Stock
ExchangesOfPreferredStockSeriesAAndBToCommonStock
3366 usd
CY2022 ltbr Payment Of Accrued Liabilities With Common Stock Non Cash
PaymentOfAccruedLiabilitiesWithCommonStockNonCash
15000 usd
CY2021 ltbr Payment Of Accrued Liabilities With Common Stock Non Cash
PaymentOfAccruedLiabilitiesWithCommonStockNonCash
69690 usd
CY2022 ltbr Share Based Compensation Arrangement By Share Based Payment Award Other Value Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherValueIncreaseDecrease
-104604 usd
CY2022 ltbr Shares Issued Registered Offerings Net Of Offering Costs Amount
SharesIssuedRegisteredOfferingsNetOfOfferingCostsAmount
11026785 usd
CY2022 ltbr Common Stock Issued To Directors And Consultants For Services Amount
CommonStockIssuedToDirectorsAndConsultantsForServicesAmount
60000 usd
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
842704 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-7497857 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
29118155 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
17207557 usd
CY2021 ltbr Exchanges Of Series Ab Preferred Stock To Common Stock Amount
ExchangesOfSeriesABPreferredStockToCommonStockAmount
0 usd
CY2021 ltbr Share Based Compensation Arrangement By Share Based Payment Award Other Value Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherValueIncreaseDecrease
-824153 usd
CY2021 ltbr Common Stock Issued Pursuant To Restricted Stock Awards Amount
CommonStockIssuedPursuantToRestrictedStockAwardsAmount
0 usd
CY2021 ltbr Common Stock Issued Registered Atm Offerings Net Of Offering Costs Amount
CommonStockIssuedRegisteredAtmOfferingsNetOfOfferingCostsAmount
14821354 usd
CY2021 ltbr Common Stock Issued Through The Exercise Of Options Amount
CommonStockIssuedThroughTheExerciseOfOptionsAmount
270857 usd
CY2021 ltbr Common Stock Issued To Directors And Consultants For Services Amount
CommonStockIssuedToDirectorsAndConsultantsForServicesAmount
324684 usd
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
826493 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-7835665 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
24791127 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p>
CY2021 ltbr Contributed Services Research And Development Expense Amount
ContributedServicesResearchAndDevelopmentExpenseAmount
500000 usd
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company will need additional funding by way of a combination of strategic alliances, government grants, further offerings of equity securities, or an offering of debt securities in order to support its future R&amp;D activities required to further enhance and complete the development of its fuel products to a proof-of-concept stage and a commercial stage thereafter.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There can be no assurance that the Company will be able to successfully continue to conduct its operations if there is a lack of financial resources available in the future to continue its fuel development activities, and a failure to do so would have a material adverse effect on the Company’s future R&amp;D activities, financial position, results of operations, and cash flows. Also, the success of the Company’s operations will be subject to other numerous contingencies, some of which are beyond management’s control. These contingencies include general and regional economic conditions, contingent liabilities, potential competition with other nuclear fuel developers, including those entities developing accident tolerant fuels, changes in government regulations, support for nuclear power, changes in accounting and taxation standards, inability to achieve overall short-term and long-term research and development milestones toward commercialization, future impairment charges to its assets, and global or regional catastrophic events. The Company may also be subject to various additional political, economic, and other uncertainties.</p>
CY2022Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2022 us-gaap Interest Income Securities Us Treasury
InterestIncomeSecuritiesUSTreasury
19900000 usd
CY2021 us-gaap Interest Income Securities Us Treasury
InterestIncomeSecuritiesUSTreasury
900000 usd
CY2022Q4 us-gaap Deposits
Deposits
9000000.0 usd
CY2021Q4 us-gaap Deposits
Deposits
15700000 usd
CY2022 ltbr Contributed Services Research And Development Expense Amount
ContributedServicesResearchAndDevelopmentExpenseAmount
400000 usd
CY2022Q4 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
100000 usd
CY2022 ltbr Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-7500000 usd
CY2021 ltbr Net Loss Attributable To Common Stockholders
NetLossAttributableToCommonStockholders
-12000000 usd
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10834574 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7035510 shares
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.71
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7500000 usd
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12000000 usd
CY2022 us-gaap Dilutive Securities
DilutiveSecurities
0 usd
CY2021 us-gaap Dilutive Securities
DilutiveSecurities
0 usd
CY2022 ltbr Net Loss Diluted
NetLossDiluted
-7500000 usd
CY2021 ltbr Net Loss Diluted
NetLossDiluted
-12000000 usd
CY2022 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
10834574 shares
CY2021 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
7035510 shares
CY2022 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0 shares
CY2021 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0 shares
CY2022 ltbr Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
10834574 shares
CY2021 ltbr Weighted Average Common Shares Outstanding
WeightedAverageCommonSharesOutstanding
7035510 shares
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.71
CY2022 ltbr Warrants Outstanding
WarrantsOutstanding
0 shares
CY2021 ltbr Warrants Outstanding
WarrantsOutstanding
45577 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
525903 shares
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
538713 shares
CY2021 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
188588 shares
CY2022 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
525903 shares
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
772878 shares
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
300000 usd
CY2022Q4 ltbr Deferred Tax Asset Valuation Allowance
DeferredTaxAssetValuationAllowance
17900000 usd
CY2021Q4 ltbr Deferred Tax Asset Valuation Allowance
DeferredTaxAssetValuationAllowance
15400000 usd
CY2022Q4 ltbr Net Operating Loss Carry Forward
NetOperatingLossCarryForward
54000000 usd
CY2022Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
200000 usd
CY2021Q4 us-gaap Accounts Payable Trade Current And Noncurrent
AccountsPayableTradeCurrentAndNoncurrent
100000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
200000 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
100000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
400000 usd
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
200000 usd
CY2022 ltbr Operating Lease Term
OperatingLeaseTerm
P12M
CY2022 ltbr Operating Lease Monthly Payment
OperatingLeaseMonthlyPayment
8000 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
100000 usd
CY2022 ltbr Operating Leases Rents Expense Net
OperatingLeasesRentsExpenseNet
100000 usd
CY2022 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
3400000 usd
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
15900000 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3100000 usd
CY2021 ltbr Patent Impairment Provision
PatentImpairmentProvision
300000 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
11700000 usd
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
300000 usd
CY2021Q4 us-gaap Operating Loss Carryforwards Valuation Allowance
OperatingLossCarryforwardsValuationAllowance
15400000 usd
CY2021 ltbr Income Tax Expense Benefits Amount
IncomeTaxExpenseBenefitsAmount
0 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.25 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.25 pure
CY2022 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
3500000 usd
CY2021 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
3100000 usd
CY2022 ltbr Provision For Patent
ProvisionForPatent
400000 usd
CY2021 ltbr Provision For Patent
ProvisionForPatent
300000 usd
CY2022Q4 ltbr Deferred Tax Asset Operating Loss Carryforwards
DeferredTaxAssetOperatingLossCarryforwards
13600000 usd
CY2021Q4 ltbr Deferred Tax Asset Operating Loss Carryforwards
DeferredTaxAssetOperatingLossCarryforwards
11700000 usd
CY2022 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
100000 usd
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
300000 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
12.92
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
18852 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.17
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.98
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022 ltbr Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
0
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1600000 usd
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1700000 usd
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-400000 usd
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-200000 usd
CY2022 ltbr Tax Benefit From Federal And State Rd Tax Credits
TaxBenefitFromFederalAndStateRDTaxCredits
0 usd
CY2021 ltbr Tax Benefit From Federal And State Rd Tax Credits
TaxBenefitFromFederalAndStateRDTaxCredits
0 usd
CY2022 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
400000 usd
CY2021 us-gaap Income Tax Reconciliation Tax Credits Other
IncomeTaxReconciliationTaxCreditsOther
0 usd
CY2022 us-gaap Real Estate Owned Valuation Allowance Valuation Increase
RealEstateOwnedValuationAllowanceValuationIncrease
2400000 usd
CY2021 us-gaap Real Estate Owned Valuation Allowance Valuation Increase
RealEstateOwnedValuationAllowanceValuationIncrease
1900000 usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
25000000 shares
CY2022Q4 ltbr Increased In Number Of Shares Issued
IncreasedInNumberOfSharesIssued
1100000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11900217 shares
CY2022Q4 ltbr Outstanding Restricted Stock Awards
OutstandingRestrictedStockAwards
416316 shares
CY2022Q4 ltbr Stock Options Outstanding
StockOptionsOutstanding
525903 shares
CY2022Q4 ltbr Total Common Stock And All Common Stock Equivalents
TotalCommonStockAndAllCommonStockEquivalents
12426120 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9759223 shares
CY2021Q4 ltbr Outstanding Restricted Stock Awards
OutstandingRestrictedStockAwards
188588 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
45577 shares
CY2021Q4 ltbr Convertible Restricted Stock
ConvertibleRestrictedStock
188588 shares
CY2021Q4 ltbr Total Common Stock And All Common Stock Equivalents
TotalCommonStockAndAllCommonStockEquivalents
10532101 shares
CY2022 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
0 usd
CY2021 us-gaap Other Interest And Dividend Income
OtherInterestAndDividendIncome
0 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
538713 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.51
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
31662 shares
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.29
CY2022 ltbr Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
2.37
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
525903 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.74
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
13.23
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
514513 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.03
CY2022 ltbr Weighted Average Fair Value Options Exercisable
WeightedAverageFairValueOptionsExercisable
13.43
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
515847 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
20.23
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
14.51
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
58164 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.72
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.58
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
30282 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.94
CY2021 ltbr Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercised In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
6.77
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3997 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
62.52
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
43.63
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1019 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
329.81
CY2021 ltbr Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
291.73
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
538713 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.51
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
12.92
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
526947 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
18.79
CY2021 ltbr Weighted Average Fair Value Options Exercisable
WeightedAverageFairValueOptionsExercisable
13.11
CY2021 ltbr Stock Option Exercise Shares Net Proceeds
StockOptionExerciseSharesNetProceeds
300000 usd
CY2021 ltbr Stock Option Exercise Shares
StockOptionExerciseShares
30282 shares
CY2022 ltbr Non Qualified Stock Options Outstanding
NonQualifiedStockOptionsOutstanding
325571 shares
CY2022 ltbr Non Qualified Stock Options Outstanding Period
NonQualifiedStockOptionsOutstandingPeriod
P10Y
CY2022 ltbr Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm
P4Y6M7D
CY2022Q4 ltbr Number Of Awards Stock Option Outstanding
NumberOfAwardsStockOptionOutstanding
525903 usd
CY2022 ltbr Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm
P4Y5M1D
CY2022Q4 ltbr Number Of Awards Vested
NumberOfAwardsVested
514513 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.03
CY2022Q4 ltbr Vesting Shares Outstanding Year One
VestingSharesOutstandingYearOne
159727 shares
CY2022Q4 ltbr Vesting Shares Outstanding Year Two
VestingSharesOutstandingYearTwo
159726 shares
CY2022Q4 ltbr Vesting Shares Outstanding Year Three
VestingSharesOutstandingYearThree
96863 shares
CY2022Q4 ltbr Vesting Shares Outstanding
VestingSharesOutstanding
416316 shares
CY2022 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
0 usd
CY2021 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
0 usd
CY2022 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
800000 usd
CY2021 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
800000 usd
CY2022 us-gaap Dividends Sharebased Compensation Stock
DividendsSharebasedCompensationStock
800000 usd
CY2021 us-gaap Dividends Sharebased Compensation Stock
DividendsSharebasedCompensationStock
800000 usd

Files In Submission

Name View Source Status
ltbr_10k_htm.xml Edgar Link completed
0001477932-23-001946-index-headers.html Edgar Link pending
0001477932-23-001946-index.html Edgar Link pending
0001477932-23-001946.txt Edgar Link pending
0001477932-23-001946-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ltbr-20221231.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ltbr-20221231_cal.xml Edgar Link unprocessable
ltbr-20221231_def.xml Edgar Link unprocessable
ltbr-20221231_lab.xml Edgar Link unprocessable
ltbr-20221231_pre.xml Edgar Link unprocessable
ltbr_10k.htm Edgar Link pending
ltbr_ex1015.htm Edgar Link pending
ltbr_ex1015img1.jpg Edgar Link pending
ltbr_ex1015img10.jpg Edgar Link pending
ltbr_ex1015img11.jpg Edgar Link pending
ltbr_ex1015img12.jpg Edgar Link pending
ltbr_ex1015img13.jpg Edgar Link pending
ltbr_ex1015img16.jpg Edgar Link pending
ltbr_ex1015img2.jpg Edgar Link pending
ltbr_ex1015img3.jpg Edgar Link pending
ltbr_ex1015img4.jpg Edgar Link pending
ltbr_ex1015img5.jpg Edgar Link pending
ltbr_ex1015img6.jpg Edgar Link pending
ltbr_ex1015img7.jpg Edgar Link pending
ltbr_ex1015img8.jpg Edgar Link pending
ltbr_ex1016.htm Edgar Link pending
ltbr_ex1016img18.jpg Edgar Link pending
ltbr_ex1016img19.jpg Edgar Link pending
ltbr_ex1016img20.jpg Edgar Link pending
ltbr_ex1016img21.jpg Edgar Link pending
ltbr_ex1016img22.jpg Edgar Link pending
ltbr_ex1016img23.jpg Edgar Link pending
ltbr_ex1016img24.jpg Edgar Link pending
ltbr_ex1016img25.jpg Edgar Link pending
ltbr_ex1016img26.jpg Edgar Link pending
ltbr_ex1016img27.jpg Edgar Link pending
ltbr_ex1017.htm Edgar Link pending
ltbr_ex1017img1.jpg Edgar Link pending
ltbr_ex1017img10.jpg Edgar Link pending
ltbr_ex1017img11.jpg Edgar Link pending
ltbr_ex1017img12.jpg Edgar Link pending
ltbr_ex1017img13.jpg Edgar Link pending
ltbr_ex1017img14.jpg Edgar Link pending
ltbr_ex1017img2.jpg Edgar Link pending
ltbr_ex1017img3.jpg Edgar Link pending
ltbr_ex1017img4.jpg Edgar Link pending
ltbr_ex1017img5.jpg Edgar Link pending
ltbr_ex1017img6.jpg Edgar Link pending
ltbr_ex1017img7.jpg Edgar Link pending
ltbr_ex1017img8.jpg Edgar Link pending
ltbr_ex1017img9.jpg Edgar Link pending
ltbr_ex1018.htm Edgar Link pending
ltbr_ex1018img1.jpg Edgar Link pending
ltbr_ex1018img2.jpg Edgar Link pending
ltbr_ex1018img3.jpg Edgar Link pending
ltbr_ex1018img4.jpg Edgar Link pending
ltbr_ex1018img5.jpg Edgar Link pending
ltbr_ex1018img6.jpg Edgar Link pending
ltbr_ex1018img7.jpg Edgar Link pending
ltbr_ex1018img8.jpg Edgar Link pending
ltbr_ex231.htm Edgar Link pending
ltbr_ex31.htm Edgar Link pending
ltbr_ex311.htm Edgar Link pending
ltbr_ex312.htm Edgar Link pending
ltbr_ex32.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending